Hannah Ceuleers

Hannah Ceuleers

Auto-generated profile, based on publicly available information

Hannah Ceuleers

Laboratory of Experimental Medicine and Pediatrics, Belgium

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in World Journal of Gastroenterology
Verified
Journal Article
Open access
HSHanne Van Spaendonk
Hanne Van Spaendonk
HCHannah Ceuleers
Hannah Ceuleers
LWLeonie Witters
Leonie Witters
EPEveline Patteet
Eveline Patteet
JJJurgen Joossens
Jurgen Joossens
BWBenedicte De Winter
Benedicte De Winter
The gastrointestinal barrier is - with approximately 400 m2 - the human body’s largest surface separating the external environment from the internal milieu. This barrier serves a dual function: permitting the absorption of nutrients, water and electrolytes on the one hand, while limiting host contact with noxious luminal antigens on the other hand. To maintain this selective barrier, junction protein complexes seal the intercellular space between adjacent epithelial cells and regulate the paracellular transport. Increased intestinal permeability is associated with and suggested as a player in the pathophysiology of various gastrointestinal and extra-intestinal diseases such as inflammatory bowel disease, celiac disease and type 1 diabetes. The gastrointestinal tract is exposed to high levels of endogenous and exogenous proteases, both in the lumen and in the mucosa. There is increasing evidence to suggest that a dysregulation of the protease/antiprotease balance in the gut contributes to epithelial damage and increased permeability. Excessive proteolysis leads to direct cleavage of intercellular junction proteins, or to opening of the junction proteins via activation of protease activated receptors. In addition, proteases regulate the activity and availability of cytokines and growth factors, which are also known modulators of intestinal permeability. This review aims at outlining the mechanisms by which proteases alter the intestinal permeability. More knowledge on the role of proteases in mucosal homeostasis and gastrointestinal barrier function will definitely contribute to the identification of new therapeutic targets for permeability-related diseases.

1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
HCHannah Ceuleers
Hannah Ceuleers
HSHanne Van Spaendonk
Hanne Van Spaendonk
NHNikita Hanning
Nikita Hanning
JHJelena Heirbaut
Jelena Heirbaut
ALAnne-Marie Lambeir
Anne-Marie Lambeir
BWBenedicte De Winter
Benedicte De Winter
Proteases, enzymes catalyzing the hydrolysis of peptide bonds, are present at high concentrations in the gastrointestinal tract. Besides their well-known role in the digestive process, they also function as signaling molecules through the activation of protease-activated receptors (PARs). Based on their chemical mechanism for catalysis, proteases can be classified into several classes: serine, cysteine, aspartic, metallo- and threonine proteases represent the mammalian protease families. In particular, the class of serine proteases will play a significant role in this review. In the last decades, proteases have been suggested to play a key role in the pathogenesis of visceral hypersensitivity, which is a major factor contributing to abdominal pain in patients with inflammatory bowel diseases and/or irritable bowel syndrome. So far, only a few preclinical animal studies have investigated the effect of protease inhibitors specifically on visceral sensitivity while their effect on inflammation is described in more detail. In our accompanying review we describe their effect on gastrointestinal permeability. On account of their promising results in the field of visceral hypersensitivity, further research is warranted. The aim of this review is to give an overview on the concept of visceral hypersensitivity as well as on the physiological and pathophysiological functions of proteases herein.

17 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ADAnnemie Deiteren
Annemie Deiteren
LLLaura van der Linden
Laura van der Linden
AWAnouk de Wit
Anouk de Wit
HCHannah Ceuleers
Hannah Ceuleers
RBRoeland Buckinx
Roeland Buckinx
BWBenedicte De Winter
Benedicte De Winter
Experiments using P2X3 knock-out mice or more general P2X receptor antagonists suggest that P2X3 receptors contribute to visceral hypersensitivity. We aimed to investigate the effect of the selective P2X3 antagonist A-317491 on visceral sensitivity under physiological conditions, during acute colitis and in the post-inflammatory phase of colitis. Trinitrobenzene sulphonic-acid colitis was monitored by colonoscopy: on day 3 to confirm the presence of colitis and then every 4 days, starting from day 10, to monitor convalescence and determine the exact timepoint of endoscopic healing in each rat. Visceral sensitivity was assessed by quantifying visceromotor responses to colorectal distension in controls, rats with acute colitis and post-colitis rats. A-317491 was administered 30 min prior to visceral sensitivity testing. Expression of P2X3 receptors (RT-PCR and immunohistochemistry) and the intracellular signalling molecules cdk5, csk and CASK (RT-PCR) were quantified in colonic tissue and dorsal root ganglia. ATP release in response to colorectal distension was measured by luminiscence. Rats with acute TNBS-colitis displayed significant visceral hypersensitivity that was dose-dependently, but not fully, reversed by A-317491. Hypersenstivity was accompanied by an increased colonic release of ATP. Post-colitis rats also displayed visceral hypersensitivity that was dose-dependently reduced and fully normalized by A-317491 without increased release of ATP. A-317491 did not modify visceral sensitivity in controls. P2X3 mRNA and protein expression in the colon and dorsal root ganglia were similar in control, acute colitis and post-colitis groups, while colonic mRNA expression of cdk5, csk and CASK was increased in the post-colitis group only. These findings indicate that P2X3 receptors are not involved in sensory signaling under physiological conditions whereas they modulate visceral hypersensitivity during acute TNBS-colitis and even more so in the post-inflammatory phase, albeit via different mechanisms of sensitization, validating P2X3 receptors as potential new targets in the treatment of abdominal pain syndromes.

17 June 2018 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
HCHannah Ceuleers
Hannah Ceuleers
NHNikita Hanning
Nikita Hanning
JHJelena Heirbaut
Jelena Heirbaut
SRSamuel Van Remoortel
Samuel Van Remoortel
JJJurgen Joossens
Jurgen Joossens
BWBenedicte De Winter
Benedicte De Winter

29 May 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NHNikita Hanning
Nikita Hanning
MBMichelle De bruyn
Michelle De bruyn
HCHannah Ceuleers
Hannah Ceuleers
TBTim Boogaerts
Tim Boogaerts
MBMaya Berg
Maya Berg
BWBenedicte De Winter
Benedicte De Winter
Dysregulation of the protease–antiprotease balance in the gastrointestinal tract has been suggested as a mechanism underlying visceral hypersensitivity in conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). We aimed to study the potential therapeutic role of an intracolonically administered serine protease inhibitor for the treatment of abdominal pain in a post-inflammatory rat model for IBS. An enema containing 2,4,6-trinitrobenzene sulfonic acid (TNBS) was used to induce colitis in male Sprague–Dawley rats, whereas controls received a saline solution. Colonoscopies were performed to confirm colitis and follow-up mucosal healing. In the post-inflammatory phase, the serine protease inhibitor UAMC-00050 (0.1–5 mg/kg) or its vehicle alone (5% DMSO in H2O) was administered in the colon. Thirty minutes later, visceral mechanosensitivity to colorectal distensions was quantified by visceromotor responses (VMRs) and local effects on colonic compliance and inflammatory parameters were assessed. Specific proteolytic activities in fecal and colonic samples were measured using fluorogenic substrates. Pharmacokinetic parameters were evaluated using bioanalytical measurements with liquid chromatography–tandem mass spectrometry. Post-inflammatory rats had increased trypsin-like activity in colonic tissue and elevated elastase-like activity in fecal samples compared to controls. Treatment with UAMC-00050 decreased trypsin-like activity in colonic tissue of post-colitis animals. Pharmacokinetic experiments revealed that UAMC-00050 acted locally, being taken up in the bloodstream only minimally after administration. Local administration of UAMC-00050 normalized visceral hypersensitivity. These results support the role of serine proteases in the pathophysiology of visceral pain and the potential of locally administered serine protease inhibitors as clinically relevant therapeutics for the treatment of IBS patients with abdominal pain.

22 May 2019 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
SRSamuel Van Remoortel
Samuel Van Remoortel
HCHannah Ceuleers
Hannah Ceuleers
RARohit Arora
Rohit Arora
LNLuc Van Nassauw
Luc Van Nassauw
JMJoris G. De Man
Joris G. De Man
JTJean-Pierre Timmermans
Jean-Pierre Timmermans